Clinical Assessment of Pain, Tolerability, and Preference of an Autoinjection Pen Versus a Prefilled Syringe for Patient Self-Administration of the Fully Human, Monoclonal Antibody Adalimumab: The TOUCH Trial

Clinical Therapeutics

Volumn 28, Issue 10, 2006, Pages 1619-1629

  Kivitz, Alan ^a   Cohen, Steven ^b   Dowd, James Edward ^c   Edwards, William ^d   Thakker, Suman ^e   Wellborne, Frank R ^f   Renz, Cheryl L ^a   Segurado, Oscar G ^g  

^a Altoona Center for Clinical Research   (United States)

^b Office of Research Administration   (United States)

^c Michigan Arthritis Research Center   (United States)

^d Low County Rheumatology   (United States)

^e Desert Valley Medical Group   (United States)

^f Houston Institute for Clinical Research   (United States)

^g ABBOTT LABORATORIES   (United States)

Author keywords

prefilled syringe, autoinjection pen, adalimumab, TNF antagonist, patient preference

Indexed keywords

ADALIMUMAB; METHOTREXATE; STEROID;

ADULT; AGED; ARTICLE; BRONCHITIS; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DRUG DELIVERY SYSTEM; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INFECTION; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PAIN; PAIN ASSESSMENT; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; RHEUMATOID ARTHRITIS; RHINITIS; SELF INJECTION; STEROID THERAPY; SYRINGE;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; HUMANS; PAIN; PATIENT COMPLIANCE; SELF ADMINISTRATION; SYRINGES;

EID: 33751528208     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.10.006     Document Type: Article

References (19)

1. Accessed August 16, 2006. HUMIRA (adalimumab) (2006), Abbott Laboratories, North Chicago, III. http://www.rxabbott.com/pdf/humira.pdf Accessed August 16, 2006
2. Weisman M.H., Moreland L.W., Furst D.E., et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: A pilot study. Clin Ther 25 (2003) 1700-1721
3. den Broeder A., van de Putte L., Rau R., et al. A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2177) in patients with rheumatoid arthritis. J Rheumatol 29 (2002) 2288-2298
4. [published correction appears in Arthritis Rheum. 2003;48:855]. Weinblatt M.E., Keystone E.C., Furst D.E., et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum 48 (2003) 35-45
5. Weinblatt M.E., Keystone E.C., Furst D.E., et al. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. Ann Rheum Dis 65 (2006) 753-759
6. Keystone E.C., Kavanaugh A.F., Sharp J.T., et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo-controlled, 52-week trial. Arthritis Rheum 50 (2004) 1400-1411
7. Breedveld F.C., Weisman M.H., Kavanaugh A.F., et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54 (2006) 26-37
8. Schiff M.H., Burmester G.R., Kent J.D., et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 65 (2006) 889-894
9. Schwartzman S., and Morgan Jr. G.J. Does route of administration affect the outcome ofTNF antagonist therapy?. Arthritis Res Ther 6 Suppl 2 (2004) S19-S23
10. Gobel H., Baar H., Beikufner H.D., et al. Practicability and acceptance of subcutaneous self-administration of the selective serotonin agonist sumatriptan. Headache 38 (1998) 267-269
11. Korytkowski M., Bell D., Jacobson C., Suwannasari R., and FlexPen Study Team. A multicenter, randomized, openlabel, comparative, two-period crossover trial of prefer ence, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther 25 (2003) 2836-2848
12. Niskanen L., Jensen L.E., Rastam J., et al. Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus. Clin Ther 26 (2004) 531-540
13. Summers K.H., Szeinbach S.L., and Lenox S.M. Preference for insulin delivery systems among current insulin users and nonusers. Clin Ther 26 (2004) 1498-1505
14. Stanhope R., Albanese A., Moyle L., and Hamill G. Optimum method for administration of biosynthetic human growth hormone: A randomised crossover trial of an Auto Injector and a pen injection system. Arch Dis Child 67 (1992) 994-997
15. Arnett F.C., Edworthy S.M., Bloch D.A., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31 (1988) 315-324
16. Huskisson F.C. Measurement of pain. Lancet 2 (1974) 1127-1131
17. Jorgensen J.T., Romsing J., Rasmussen M., et al. Pain assessment of subcutaneous injections. Ann Pharmacother 30 (1996) 729-732
18. Furst D.F., Schiff M.H., Fleischmann R.M., et al. Adalimumab, a fully human anti tumor necrosis factor alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: Results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 30 (2003) 2563-2571
19. Ritter P.L., Gonzalez V.M., Laurent D.D., and Lorig K.R. Measurement of pain using the visual numeric scale. J Rheumatol 33 (2006) 574-580